Arixtra

Active Ingredient(s): Fondaparinux
FDA Approved: * December 7, 2001
Pharm Company: * GLAXOSMITHKLINE
Category: Blood Thinner (Anticoagulant)

Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by GlaxoSmithKline. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories. Contents 1 Medical uses 1.1 Comparison to other agents 2 Pharmacology 2.1 Mechanism of action 3 Chemistry 3.1 Abbreviations 4 References 5 External links Medical uses Clinically, it is used for the prevention of deep vein thrombosis ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Arixtra 2.5 mg/.5ml Subcutaneous Injection, Solution
NDC: 0007-3230
Labeler:
Glaxosmithkline LLC
Arixtra 5 mg/.4ml Subcutaneous Injection, Solution
NDC: 0007-3232
Labeler:
Glaxosmithkline LLC
Arixtra 7.5 mg/.6ml Subcutaneous Injection, Solution
NDC: 0007-3234
Labeler:
Glaxosmithkline LLC
Arixtra 10 mg/.8ml Subcutaneous Injection, Solution
NDC: 0007-3236
Labeler:
Glaxosmithkline LLC
Arixtra 7.5 mg/.6ml Subcutaneous Injection, Solution
NDC: 54868-5501
Labeler:
Physicians Total Care, Inc.
Arixtra 2.5 mg/.5ml Subcutaneous Injection, Solution
NDC: 67457-592
Labeler:
Mylan Institutional LLC
Arixtra 5 mg/.4ml Subcutaneous Injection, Solution
NDC: 67457-593
Labeler:
Mylan Institutional LLC
Arixtra 7.5 mg/.6ml Subcutaneous Injection, Solution
NDC: 67457-594
Labeler:
Mylan Institutional LLC
Arixtra 10 mg/.8ml Subcutaneous Injection, Solution
NDC: 67457-595
Labeler:
Mylan Institutional LLC